CONTEXT: Imaging and post-mortem studies provide converging evidence that patients with schizophrenia have a dysregulated developmental trajectory of frontal lobe myelination even in adulthood. Atypical antipsychotics have been shown to have a wide spectrum of efficacy across multiple psychiatric diseases and to be particularly efficacious in treatment resistant cases of disorders such as schizophrenia. OBJECTIVE: To test the a priori hypothesis that antipsychotic medications may differentially impact frontal lobe myelination in patients with schizophrenia. DESIGN, SETTING, AND PARTICIPANTS: Participants ranged in age from 18-35 years, were all male, and were recruited by a single group of investigators using the same criteria. Two cohorts of subjects with schizophrenia early in their disease who were treated either with oral risperidone (Ris) or fluphenazine decanoate (Fd) were imaged in conjunction with cohorts of healthy controls. Each cohort was imaged using a different MRI instrument using identical imaging sequences. MAIN OUTCOME MEASURE: MRI measures of frontal lobe white matter volume. RESULTS: We estimated differences due to differences in the MRI instruments used in the two studies in the two healthy control groups matched to the patient samples, adjusting for age and other covariates. We then statistically removed those differences (which we assumed were due to instrument effects) from the data in the schizophrenia samples by subtraction. Relative to the differences seen in controls, the two groups of schizophrenic patients differed in their pattern of frontal lobe structure with the Ris-treated group having significantly larger white matter volume than the Fd group. CONCLUSIONS: The results suggest that the choice of antipsychotic treatment may differentially impact brain myelination in adults with schizophrenia. Prospective studies are needed to confirm this finding. MRI can be used to dissect subtle differences in brain tissue characteristics and thus could help clarify the effect of pharmacologic treatments on neurodevelopmental and pathologic processes in vivo.
CONTEXT: Imaging and post-mortem studies provide converging evidence that patients with schizophrenia have a dysregulated developmental trajectory of frontal lobe myelination even in adulthood. Atypical antipsychotics have been shown to have a wide spectrum of efficacy across multiple psychiatric diseases and to be particularly efficacious in treatment resistant cases of disorders such as schizophrenia. OBJECTIVE: To test the a priori hypothesis that antipsychotic medications may differentially impact frontal lobe myelination in patients with schizophrenia. DESIGN, SETTING, AND PARTICIPANTS: Participants ranged in age from 18-35 years, were all male, and were recruited by a single group of investigators using the same criteria. Two cohorts of subjects with schizophrenia early in their disease who were treated either with oral risperidone (Ris) or fluphenazine decanoate (Fd) were imaged in conjunction with cohorts of healthy controls. Each cohort was imaged using a different MRI instrument using identical imaging sequences. MAIN OUTCOME MEASURE: MRI measures of frontal lobe white matter volume. RESULTS: We estimated differences due to differences in the MRI instruments used in the two studies in the two healthy control groups matched to the patient samples, adjusting for age and other covariates. We then statistically removed those differences (which we assumed were due to instrument effects) from the data in the schizophrenia samples by subtraction. Relative to the differences seen in controls, the two groups of schizophrenicpatients differed in their pattern of frontal lobe structure with the Ris-treated group having significantly larger white matter volume than the Fd group. CONCLUSIONS: The results suggest that the choice of antipsychotic treatment may differentially impact brain myelination in adults with schizophrenia. Prospective studies are needed to confirm this finding. MRI can be used to dissect subtle differences in brain tissue characteristics and thus could help clarify the effect of pharmacologic treatments on neurodevelopmental and pathologic processes in vivo.
Authors: Kevin M Spencer; Paul G Nestor; Ruth Perlmutter; Margaret A Niznikiewicz; Meredith C Klump; Melissa Frumin; Martha E Shenton; Robert W McCarley Journal: Proc Natl Acad Sci U S A Date: 2004-11-16 Impact factor: 11.205
Authors: T Li; H Stefansson; E Gudfinnsson; G Cai; X Liu; R M Murray; V Steinthorsdottir; D Januel; V G Gudnadottir; H Petursson; A Ingason; J R Gulcher; K Stefansson; D A Collier Journal: Mol Psychiatry Date: 2004-07 Impact factor: 15.992
Authors: Natalya A Uranova; Victor M Vostrikov; Diana D Orlovskaya; Valentina I Rachmanova Journal: Schizophr Res Date: 2004-04-01 Impact factor: 4.939
Authors: Maria Angelique Di Biase; Vanessa L Cropley; Luca Cocchi; Alexander Fornito; Fernando Calamante; Eleni P Ganella; Christos Pantelis; Andrew Zalesky Journal: Schizophr Bull Date: 2019-06-18 Impact factor: 9.306
Authors: Wendy R Kates; Amy K Olszewski; Matthew H Gnirke; Zora Kikinis; Joshua Nelson; Kevin M Antshel; Wanda Fremont; Petya D Radoeva; Frank A Middleton; Martha E Shenton; Ioana L Coman Journal: Schizophr Res Date: 2014-07-25 Impact factor: 4.939
Authors: George Bartzokis; Po H Lu; Erika P Raven; Chetan P Amar; Nicole R Detore; Alexander J Couvrette; Jim Mintz; Joseph Ventura; Laurie R Casaus; John S Luo; Kenneth L Subotnik; Keith H Nuechterlein Journal: Schizophr Res Date: 2012-07-17 Impact factor: 4.939
Authors: Sarah L M Johnson; Deanna Greenstein; Liv Clasen; Rachel Miller; Francois Lalonde; Judith Rapoport; Nitin Gogtay Journal: Psychiatry Res Date: 2012-11-13 Impact factor: 3.222
Authors: Philip R Szeszko; Delbert G Robinson; Toshikazu Ikuta; Bart D Peters; Juan A Gallego; John Kane; Anil K Malhotra Journal: Neuropsychopharmacology Date: 2013-10-16 Impact factor: 7.853
Authors: Lindsay D Jones; Martha E Payne; Denise F Messer; John L Beyer; James R MacFall; K Ranga R Krishnan; Warren D Taylor Journal: J Affect Disord Date: 2008-08-08 Impact factor: 4.839
Authors: George Bartzokis; Po H Lu; Stephanie B Stewart; Bolanle Oluwadara; Andrew J Lucas; Joanna Pantages; Erika Pratt; Jonathan E Sherin; Lori L Altshuler; Jim Mintz; Michael J Gitlin; Kenneth L Subotnik; Keith H Nuechterlein Journal: Schizophr Res Date: 2009-07-17 Impact factor: 4.939